A Phase 2 interventional study of ONO-1110 and Placebo in Fibromyalgia, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 30 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Fibromyalgia
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
This study's enrollment of 175 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Browse Fibromyalgia studies →Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONO-1110 tablets once a day
Drug: ONO-1110
Placebo tablets once daily
Drug: Placebo
ONO-1110 tablets once a day
Placebo tablets once daily
Change in weekly mean of average pain score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
Adverse events
Time frame: Up to 16 weeks
Change in weekly mean of average pain score from baseline in each week
Time frame: Up to 16 weeks
30%- and 50%-responder rates based on the weekly mean of average pain score
proportions of participants whose weekly mean of average pain score has decreased by 30% and 50% from baseline, respectively
Time frame: Up to 16 weeks
Change in weekly mean of worst pain score from baseline to each week
Time frame: Up to 16 weeks
30%- and 50%-responder rates based on the weekly mean of worst pain score
proportions of participants whose weekly mean of worst pain score has decreased by 30% and 50% from baseline, respectively
Time frame: Up to 16 weeks
Change in WPI and SSS score of 2016 Revised FM Diagnostic Criteria by ACR from baseline
Time frame: Up to 16 weeks
Change in Japanese version of the Revised Fibromyalgia Impact Questionnaire (JFIQR) score from baseline
Time frame: Up to 16 weeks
Change in Patient Global Impression of Change (PGIC) score from baseline
Time frame: Up to 16 weeks
Change in Hospital Anxiety and Depression Scale (HADS) score from baseline
Time frame: Up to 16 weeks
Change in Medical Outcomes Study Sleep Scale (MOS-Sleep Scale) score from baseline
Time frame: Up to 16 weeks
Plasma ONO-1110 concentrations
Time frame: Up to 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in May 2026, 14 months.
Of 24 phase 2 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-1110
Ono Pharmaceutical Co., Ltd. →